On September 14, 2020, NiKang Therapeutics, an early stage biotech company focused on developing novel small molecule oncology drug discovery, announced the completion of a Series B financing for $50 million. The financing was led by RTW Investments, LP, with additional support from existing investor CBC Group, and from new investors including Lilly Asia Ventures, Casdin Capital, HBM Healthcare Investments, Matrix Partners China, and Octagon Capital. Wilson Sonsini Goodrich & Rosati advised NiKang Therapeutics in the transaction.

According to the press release, NiKang will use the proceeds to support the preclinical and clinical development of several promising oncology programs and further enhance the company’s drug discovery pipeline. The company’s co-Founder and President, Zenhai Gao, Ph.D., notes, “With this round of financing, we are well-positioned to advance our innovative therapeutics pipeline to help patients with unmet medical needs.”

The Wilson Sonsini team advising NiKang Therapeutics includes partner Dan Koeppen, associate Kassandra Castillo, and venture counsel Tim Conroy.

Please see NiKang’s press release for more information.